Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study

Basit Öğe Kaydı
dc.authorscopusid54980627800
dc.authorscopusid57193238894
dc.authorscopusid57205580317
dc.authorscopusid57221528630
dc.authorscopusid57222142906
dc.authorscopusid56891371400
dc.authorscopusid7006046625
dc.contributor.authorÖzcan E.
dc.contributor.authorKüçükarda A.
dc.contributor.authorGökyer A.
dc.contributor.authorSayin S.
dc.contributor.authorGökmen İ.
dc.contributor.authorHacioğlu M.B.
dc.contributor.authorErdoğan B.
dc.date.accessioned2024-06-12T10:26:03Z
dc.date.available2024-06-12T10:26:03Z
dc.date.issued2023
dc.description.abstractObjective: This study aimed to compare the clinical features, prognosis, and survival rates of patients with small cell carcinoma of the lung or extrapulmonary origin to get a new perspective for customized treatment strategies for both diseases. Material and Methods: We evaluated 254 patients with either small cell lung carcinoma (SCLC) or extrapulmonary small cell carcinoma (EPSCC) who were diagnosed and treated at Trakya University Hospital, Department of Medical Oncology from 2010 to 2020. We also compared these groups re-garding their disease control rate, disease-free survival (DFS) in the limited disease (LD) stage, radiological progression-free survival (PFS), and overall survival (OS). Results: The SCLC group showed a male predominance, which was statistically significant. There was a statistically significant difference was observed concerning bone and brain metastases in the SCLC group. The median DFS was 16.7 and 9.4 months in the EPSCC and the SCLC groups with LD, respectively. Additionally, PFS and OS were similar between LD and extensive disease (ED) stage patients, respectively. Several factors like the presence of liver metastasis at the time of diagnosis, patients >60 years, poor performance status, and high lactate dehydrogenase (LDH) levels were associated with poor OS in ED patients. Conclusion: Although a significant difference was observed in DFS between both groups in LD patients, there was no significant difference between OS and PFS in LD and ED patients of SCLC and EPSCC groups, respectively. Moreover, the presence of liver metastasis and high LDH levels were a few factors that negatively affected the OS of patients. © 2023 by Turkish Society of Medical Oncology.en_US
dc.identifier.doi10.37047/jos.2023-97197
dc.identifier.endpage141en_US
dc.identifier.issn2651-4532
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85178254985en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage134en_US
dc.identifier.urihttps://doi.org/10.37047/jos.2023-97197
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16657
dc.identifier.volume9en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofJournal of Oncological Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDisease-Free Survival; Lung Neoplasms; Small Cell Carcinomaen_US
dc.subjectLactate Dehydrogenase; Adult; Article; Brain Metastasis; Clinical Feature; Controlled Study; Disease Free Survival; Extrapulmonary Small Cell Carcinoma; Female; Human; Human Tissue; Liver Metastasis; Major Clinical Study; Male; Middle Aged; Non Small Cell Lung Cancer; Overall Survival; Progression Free Survival; Retrospective Study; Small Cell Carcinoma; Small Cell Lung Cancer; Special Situation For Pharmacovigilance; Survival Rateen_US
dc.titleComparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu